MERRIMACK PHARMACEUTICALS IN (MACK) Fundamental Analysis & Valuation

NASDAQ:MACK • US5903282094

Current stock price

15.13 USD
0 (0%)
At close:
15.16 USD
+0.03 (+0.2%)
After Hours:

This MACK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MACK Profitability Analysis

1.1 Basic Checks

  • In the past year MACK was profitable.
  • In the past year MACK has reported a negative cash flow from operations.
  • In the past 5 years MACK always reported negative net income.
  • MACK had a negative operating cash flow in each of the past 5 years.
MACK Yearly Net Income VS EBIT VS OCF VS FCFMACK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

1.2 Ratios

  • MACK has a Return On Assets of 82.05%. This is amongst the best in the industry. MACK outperforms 100.00% of its industry peers.
  • MACK has a better Return On Equity (90.44%) than 99.66% of its industry peers.
Industry RankSector Rank
ROA 82.05%
ROE 90.44%
ROIC N/A
ROA(3y)-10.25%
ROA(5y)-26.93%
ROE(3y)-10.57%
ROE(5y)-30.09%
ROIC(3y)N/A
ROIC(5y)N/A
MACK Yearly ROA, ROE, ROICMACK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

  • MACK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MACK Yearly Profit, Operating, Gross MarginsMACK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MACK Health Analysis

2.1 Basic Checks

  • MACK has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for MACK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MACK Yearly Shares OutstandingMACK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
MACK Yearly Total Debt VS Total AssetsMACK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 4.99 indicates that MACK is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.99, MACK is doing good in the industry, outperforming 78.56% of the companies in the same industry.
  • MACK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.99
ROIC/WACCN/A
WACCN/A
MACK Yearly LT Debt VS Equity VS FCFMACK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

  • MACK has a Current Ratio of 10.78. This indicates that MACK is financially healthy and has no problem in meeting its short term obligations.
  • MACK has a Current ratio of 10.78. This is in the better half of the industry: MACK outperforms 79.42% of its industry peers.
  • MACK has a Quick Ratio of 10.78. This indicates that MACK is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 10.78, MACK is doing good in the industry, outperforming 79.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.78
Quick Ratio 10.78
MACK Yearly Current Assets VS Current LiabilitesMACK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MACK Growth Analysis

3.1 Past

  • MACK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10764.04%, which is quite impressive.
EPS 1Y (TTM)10764.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69750%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MACK Yearly Revenue VS EstimatesMACK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 20M 40M 60M 80M 100M
MACK Yearly EPS VS EstimatesMACK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 0 10 -10 20 30

More info and screens

Find the best growth stocksShow best growing peers

2

4. MACK Valuation Analysis

4.1 Price/Earnings Ratio

  • MACK is valuated cheaply with a Price/Earnings ratio of 1.09.
  • Based on the Price/Earnings ratio, MACK is valued cheaply inside the industry as 99.14% of the companies are valued more expensively.
  • MACK's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.75.
Industry RankSector Rank
PE 1.09
Fwd PE N/A
MACK Price Earnings VS Forward Price EarningsMACK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MACK Per share dataMACK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MACK Dividend Analysis

5.1 Amount

  • MACK has a Yearly Dividend Yield of 99.80%, which is a nice return.
  • MACK's Dividend Yield is rather good when compared to the industry average which is at 1.28. MACK pays more dividend than 99.83% of the companies in the same industry.
  • MACK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 99.8%

5.2 History

  • MACK is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MACK Yearly Dividends per shareMACK Yearly Dividends per shareYearly Dividends per share 2019 2024 5 10 15

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
MACK Yearly Income VS Free CF VS DividendMACK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

More info and screens

Find the best dividend stocksShow peers with best dividend

MACK Fundamentals: All Metrics, Ratios and Statistics

MERRIMACK PHARMACEUTICALS IN

NASDAQ:MACK (5/17/2024, 8:11:51 PM)

After market: 15.16 +0.03 (+0.2%)

15.13

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13
Earnings (Next)08-01
Inst Owners4.89%
Inst Owner Change0%
Ins Owners32.31%
Ins Owner Change0%
Market Cap223.77M
Revenue(TTM)N/A
Net Income(TTM)200.46M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 99.8%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.09
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)13.86
EY91.61%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS14.99
TBVpS14.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 82.05%
ROE 90.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.25%
ROA(5y)-26.93%
ROE(3y)-10.57%
ROE(5y)-30.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.78
Quick Ratio 10.78
Altman-Z 4.99
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10764.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69750%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1804.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1804.62%
OCF growth 3YN/A
OCF growth 5YN/A

MERRIMACK PHARMACEUTICALS IN / MACK Fundamental Analysis FAQ

What is the fundamental rating for MACK stock?

ChartMill assigns a fundamental rating of 3 / 10 to MACK.


What is the valuation status of MERRIMACK PHARMACEUTICALS IN (MACK) stock?

ChartMill assigns a valuation rating of 0 / 10 to MERRIMACK PHARMACEUTICALS IN (MACK). This can be considered as Overvalued.


What is the profitability of MACK stock?

MERRIMACK PHARMACEUTICALS IN (MACK) has a profitability rating of 2 / 10.


Can you provide the PE and PB ratios for MACK stock?

The Price/Earnings (PE) ratio for MERRIMACK PHARMACEUTICALS IN (MACK) is 1.09 and the Price/Book (PB) ratio is 1.01.